☆ 4.8 Article

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

LANCET (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Nina Le Bert et al.

Summary: The efficacy of virus-specific T cells in clearing pathogens involves a delicate balance between antiviral and inflammatory responses. Asymptomatic individuals clearing SARS-CoV-2 showed increased production of IFN-gamma and IL-2, along with a proportional secretion of IL-10 and proinflammatory cytokines, while symptomatic individuals displayed a disproportionate secretion of inflammatory cytokines triggered by SARS-CoV-2-specific T cell activation.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021

Julianne Gee et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Alexandra J. Spencer et al.

Summary: The study suggests that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine against SARS-CoV-2 in mice leads to higher antibody responses and superior cellular immune responses compared to homologous vaccination regimens.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

Shirin Kalimuddin et al.

Summary: The study showed that spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the Pfizer/Bio-NTech BNT162b2 vaccine, suggesting that early T cell and binding antibody responses may induce early protection against COVID-19 compared to receptor blocking or virus neutralizing activity.

MED (2021)

添加到收藏夹

Article Infectious Diseases

Validation of a commercially available SARS-CoV-2 serological immunoassay

B. Meyer et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

添加到收藏夹

Editorial Material Nursing

Sex-Based Vaccine Response in the Context of COVID-19

Patricia Robin McCartney

JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A thermostable, closed SARS-CoV-2 spike protein trimer

Xiaoli Xiong et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

Review Immunology

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

Kimia Kardani et al.

VACCINE (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.